Literature DB >> 2676018

Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences.

T E Hansen-Hagge1, S Yokota, C R Bartram.   

Abstract

Human T-cell receptor (TCR) delta-chain diversity mainly originates from high junctional variability, since only a limited number of germline elements is available. This extraordinary diversity at the V.J junction, due to the use of two D delta elements and extensive incorporation of N nucleotides, constitutes a specific clonal marker for cell populations exhibiting rearranged TCR delta genes. To this end we amplified in vitro by polymerase chain reaction (PCR) the TCR delta junctional region of five acute lymphoblastic leukemias (ALL), isolated respective DNA fragments, and used them directly as clonospecific probes. The combination of PCR technology and hybridization to clonospecific probes permitted the detection of leukemia DNA at dilution of 1:100,000 in all five cases. Moreover, we were able to investigate one of the ALL patients 11 months after achieving continuous complete remission. Conventional Southern blot analysis failed to detect rearranged TCR genes at this stage. However, residual leukemic cells could readily be detected by PCR technique. We conclude that the strategy proposed here is a very sensitive tool to detect minimal residual disease in a significant proportion of human lymphoid neoplasias.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2676018

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Molecular biology in medicine.

Authors:  B D Young
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

2.  Molecular genetic analysis of DNA obtained from fixed, air dried or paraffin embedded sources.

Authors:  K Grünewald; J Lyons; T E Hansen-Hagge; J W Janssen; H Feichtinger; C R Bartram
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

3.  The study of minimal residual disease in acute lymphoblastic leukaemia.

Authors:  C J Knechtli; N J Goulden; K Langlands; M N Potter
Journal:  Clin Mol Pathol       Date:  1995-04

Review 4.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

Review 5.  Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 6.  The polymerase chain reaction in diagnosing lymphoid disorders.

Authors:  K P McCarthy; D N Slack; J P Sloane
Journal:  Mol Biol Rep       Date:  1994-01       Impact factor: 2.316

7.  Assessment of clonality in lymphoid proliferations.

Authors:  L M Weiss; D V Spagnolo
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

8.  Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment.

Authors:  Claus R Bartram; André Schrauder; Rolf Köhler; Martin Schrappe
Journal:  Dtsch Arztebl Int       Date:  2012-10-05       Impact factor: 5.594

Review 9.  Gene rearrangements and chromosomal translocations in T cell lymphoma--diagnostic applications and their limits.

Authors:  H Griesser
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.

Authors:  Obul R Bandapalli; Martin Zimmermann; Corinne Kox; Martin Stanulla; Martin Schrappe; Wolf-Dieter Ludwig; Rolf Koehler; Martina U Muckenthaler; Andreas E Kulozik
Journal:  Haematologica       Date:  2013-01-24       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.